Introduction Long considered an orphan disease until recent years, hidradenitis suppurativa (HS) is rapidly gaining attention in the healthcare field with a growing spotlight on investigating HS pathogenesis, epidemiology, and…
Introduction Topical therapy is a mainstay of dermatological treatment and holds many advantages, including ease of use, relative lack of systemic side effects, and patient-directed application. In hidradenitis suppurativa (HS),…
Introduction Hidradenitis suppurativa (HS) is an inflammatory condition characterized by painful and sometimes purulent nodules, abscesses, and sinus tracts located in intertriginous regions. Lesions may progress to form hypertrophic scars…
Introduction The pathogenic model of hidradenitis suppurativa (HS) may be in the midst of a paradigm shift, balancing the initial model of a disorder of (primary) follicular occlusion with consideration…
Introduction Hidradenitis suppurativa (HS) is a disabling chronic inflammatory disease with significant comorbidities that affects an estimated 1% of the Western population. A poor understanding of HS biology has limited…
Introduction Over time, repeated episodes of hidradenitis suppurativa (HS) disease flares can lead to a number of debilitating cutaneous, systemic, as well as psychological and social complications. Given the progressive…
Introduction HS represents a prime candidate to bridge diseases of the integument and comorbid systemic disease, as a chronic inflammatory disease of the pilosebaceous unit characterized by inflammatory nodules, suppuration…
Overview of Patient Population with HS Prior to Initiating Therapy Hidradenitis suppurativa is a clinical diagnosis based on history, physical exams, patterns of recurrence, types of lesions, and scarring. No…
